Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer: A Phase II Single Arm Prospective Study

NCT02342587 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02342587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02342587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer: A Phase II Single Arm Prospective Study
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
December 3, 2014
Completion date
August 21, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive refractory advanced cancer